<?xml version="1.0" encoding="UTF-8"?>
<p id="Par112">Patients will be followed at 3 monthly intervals. At each visit, the investigator will assess the patient for the following: 
 <list list-type="bullet">
  <list-item>
   <p id="Par113">ECOG Performance status.</p>
  </list-item>
  <list-item>
   <p id="Par114">Tumour Evaluation: 
    <list list-type="bullet">
     <list-item>
      <p id="Par115">◦ CT Chest, Abdomen and Pelvis OR FDG PET/CT (Investigator to keep imaging consistent for each patient).</p>
     </list-item>
     <list-item>
      <p id="Par116">◦ For patients who have had a bone scan showing progressive disease without CT changes, FDG PET/CT is recommended to confirm progression.</p>
     </list-item>
     <list-item>
      <p id="Par117">◦ High contrast CT or MRI brain (if clinically indicated).</p>
     </list-item>
     <list-item>
      <p id="Par118">◦ MRI spine (if clinically indicated).</p>
     </list-item>
    </list>
   </p>
  </list-item>
  <list-item>
   <p id="Par119">Treatment related toxicity assessment as per NCI CTCAE v5.0</p>
  </list-item>
 </list>
</p>
